Search
Poziotinib
go.drugbank.com/drugs/DB12114InvestigationalPoziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB,
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
go.drugbank.com/drugs/DB15235InvestigationalDi-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced
Betameprodine
go.drugbank.com/drugs/DB01552ExperimentalIllicitBetameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. … The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine.
Ioforminol
go.drugbank.com/drugs/DB12439InvestigationalIoforminol has been used in trials studying the diagnostic of Cardio Renal Safety in High-risk Elderly Subjects Undergoing a Coronary CATH With or Without PCI.
ABBV-706
go.drugbank.com/drugs/DB18710InvestigationalABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161]
Zorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body.
N-(carboxycarbonyl)-D-phenylalanine
go.drugbank.com/drugs/DB08263ExperimentalN-(carboxycarbonyl)-D-phenylalanine is a solid. This compound belongs to the n-acyl-alpha amino acids. … These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. It targets the protein hypoxia-inducible factor 1-alpha inhibitor.
Synonyms: N-(carboxycarbonyl)-D-phenylalanineCyclo(prolylglycyl)
go.drugbank.com/drugs/DB04541InvestigationalNA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy